# A Phase I/II Study of ODX (Osteodex) in Metastatic Castration Resistant Prostate Cancer (CRPC)

> **NCT01595087** · PHASE1,PHASE2 · COMPLETED · sponsor: **DexTech Medical AB** · enrollment: 28 (actual)

## Conditions studied

- Prostate Cancer Metastatic

## Interventions

- **DRUG:** Osteodex

## Key facts

- **NCT ID:** NCT01595087
- **Lead sponsor:** DexTech Medical AB
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-01
- **Primary completion:** 2013-06
- **Final completion:** 2013-09
- **Target enrollment:** 28 (ACTUAL)
- **Last updated:** 2014-11-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01595087

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01595087, "A Phase I/II Study of ODX (Osteodex) in Metastatic Castration Resistant Prostate Cancer (CRPC)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01595087. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*